This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Idera To Provide Update On Programs At Stifel Nicolaus Healthcare Conference

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today will provide a further update on its autoimmune program, and its plans for initiating clinical development in genetically defined forms of B-cell lymphoma, in a presentation at the Stifel Nicolaus 2013 Healthcare Conference in Boston.

Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera Pharmaceuticals, and Jim Geraghty, Chairman of Idera’s Board of Directors, will highlight several ways in which the company has recently strengthened its business. They will provide an update on progress in the company's ongoing Phase 2 trial of its lead candidate, IMO-8400, a TLR 7, 8 and 9 antagonist, present the path forward for the company’s recently announced B-cell lymphoma program, and describe the company’s plans to expand its pipeline with the development of additional preclinical compounds.

Idera’s B-cell lymphoma program leverages an emerging scientific understanding of the central role that Toll-like Receptors (TLRs) 7 and 9 play in several forms of B-cell lymphoma with specific mutations, including activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia, and others. The company’s proprietary TLR antagonists have been shown to effectively inhibit TLR 7 and 9 in preclinical studies and in a completed Phase 2 clinical proof-of-concept study in psoriasis.

Existing safety data on IMO-8400 would enable Idera to submit an IND for IMO-8400 in Q4 2013, and initiate a Phase 1/2 clinical trial of IMO-8400 in lymphoma patients with these specific mutations in Q1 2014. The company is currently considering its options for financing this program, and would begin clinical development following the successful completion of these plans.

“We are making rapid progress in turning emerging findings in certain forms of B-cell lymphoma into a clinical development program, and hope to begin dosing the first patients early next year,” Dr. Agrawal said. “Despite notable advances, success in treating B-cell lymphoma has been limited, and patients with certain genetically defined mutations remain in desperate need of new treatments. We believe the limited number and severe condition of these patients may support regulatory designations that would allow us to advance these programs rapidly.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,217.75 -70.88 -0.39%
S&P 500 2,105.30 -12.09 -0.57%
NASDAQ 4,976.19 -31.9060 -0.64%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs